drugset / Trial / NCT00800462
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
Phase 4
Completed
23 enrolled
Toronto Rehabilitation Institute
Ontario Neurotrauma Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
Timeline
- Start
- 2008-03
- Primary completion
- 2012-06
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darifenacin | Small molecule | 15 mg | — |
| Comparator | Oxybutynin | Small molecule | 15 mg | — |
| Comparator | Trospium | Small molecule | 20 mg | — |